Oetgen Stephen Duane 4

What Happened

• Stephen Duane Oetgen, a director of Arxis, Inc. (ARXS), made two transactions reported on April 17, 2026: an open-market/direct purchase of 25,000 shares at $28.00 per share (total $700,000) and an award of 5,357 restricted stock units (RSUs) with $0 acquisition price. The RSUs are awards that are scheduled to vest on the first anniversary of the grant.

Key Details

• Transaction date: 2026-04-17; Form 4 filed: 2026-04-20 (reporting period listed as 2026-04-17).
• Purchase: 25,000 shares at $28.00 each — total consideration $700,000 (reported as a directed share purchase in connection with the issuer’s IPO).
• Award: 5,357 RSUs granted (acquisition price reported as $0); these RSUs vest on the first anniversary of the grant (per footnote).
• Shares owned after the transactions: not specified in the information provided in this summary.
• Footnotes: F1 = RSUs vest one year after grant. F2 = Purchase was through the directed share program tied to the IPO.

Context

• The 25,000-share purchase is a direct insider buy (often seen as a stronger signal than routine sales), while the RSUs are a time‑vesting equity award and are not immediately tradable until they vest. The purchase was reported via a Form 4 filed three days after the transaction date.